Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000685-39
    Sponsor's Protocol Code Number:NN9931-4296
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-12-09
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-000685-39
    A.3Full title of the trial
    Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.
    A 72-week randomised, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial
    Investigación sobre la eficacia y la seguridad de tres niveles de dosis de semaglutida subcutánea administrada una vez al día frente a placebo en sujetos con esteatohepatitis no alcohólica.
    Ensayo clínico de 72 semanas de duración, aleatorizado, doble-ciego, controlado con placebo, con tres grupos paralelos, multicéntrico, multinacional
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.
    Investigación sobre la eficacia y la seguridad de tres niveles de dosis de semaglutida subcutánea administrada una vez al día frente a placebo en sujetos con esteatohepatitis no alcohólica.
    A.4.1Sponsor's protocol code numberNN9931-4296
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1179-7464
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovo Nordisk A/S
    B.1.3.4CountryDenmark
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovo Nordisk A/S
    B.4.2CountryDenmark
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovo Nordisk A/S
    B.5.2Functional name of contact pointGlobal Clinical Registry (GCR,1452)
    B.5.3 Address:
    B.5.3.1Street AddressNovo Allé
    B.5.3.2Town/ cityBagsværd
    B.5.3.3Post code2880
    B.5.3.4CountryDenmark
    B.5.6E-mailclinicaltrials@novonordisk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSemaglutide B 1 mg/ml NovoPen4
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNsemaglutide
    D.3.9.1CAS number 910463-68-2
    D.3.9.3Other descriptive nameSEMAGLUTIDE
    D.3.9.4EV Substance CodeSUB32188
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1.0
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Non-alcoholic steatohepatitis
    Esteatohepatitis no alcohólica
    E.1.1.1Medical condition in easily understood language
    Non-alcoholic steatohepatitis (NASH)
    Esteatohepatitis no alcohólica (EHNA)
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10053219
    E.1.2Term Non-alcoholic steatohepatitis
    E.1.2System Organ Class 10019805 - Hepatobiliary disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the effect of semaglutide subcutaneous (s.c.) once daily versus placebo on histological resolution of non-alcoholic steatohepatitis (NASH).
    Comparar el efecto de la semaglutida SC administrada una vez al día frente a placebo en la resolución histológica de la EHNA.
    E.2.2Secondary objectives of the trial
    1. To investigate the dose-response relationship of three dose levels of semaglutide s.c. once daily (0.1 mg/day, 0.2 mg/day and 0.4 mg/day) on histological resolution of NASH.
    2. To compare the effects of semaglutide s.c. once daily to placebo on liver-related histological parameters and biomarkers of NASH disease.
    1. Investigar la relación dosis-respuesta de tres niveles de dosis de semaglutida SC administrada una vez al día (0,1 mg/día, 0,2 mg/día y 0,4 mg/día) en la resolución histológica de la EHNA.
    2. Comparar los efectos de semaglutida SC administrada una vez al día frente a placebo en los parámetro histológicos relacionados con el hígado y los biomarcadores relacionados con la enfermedad de EHNA.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
    2. Male or female, aged 18-75 years (both inclusive) (for Japan: male or female aged 20-75 years (both inclusive) at the time of signing informed consent.
    3. Local histological diagnosis of NASH followed by histological confirmation of NASH based on central pathologist evaluation of a liver biopsy obtained up to 21 weeks before screening.
    4. A histological NAS > = 4 with a score of 1 or more in each sub-component of the score based on central pathologist evaluation.
    5. NASH fibrosis stage 2 or 3 according to the NASH CRN fibrosis staging system based on central pathologist evaluation.
    1. Se tendrá que obtener el consentimiento informado antes de realizar ninguna actividad relacionada con el ensayo. Se consideran actividades relacionadas con el ensayo todos los procedimientos realizados como parte del mismo, incluidas las actividades realizadas con el fin de determinar la idoneidad para participar en el ensayo.
    2. Varones o mujeres de 18 a 75 años de edad (ambos inclusive) (en Japón: varones o mujeres de 20 a 75 años de edad (ambos inclusive) en el momento de firmar el consentimiento informado.
    3. Diagnóstico histológico local de EHNA seguido de confirmación histológica de EHNA, según la evaluación realizada por un anatomopatólogo central de una biopsia hepática obtenida hasta 21 semanas antes de la selección.
    4. NAS histológico > 4 con una puntuación de 1 o más en cada subcomponente del índice, según la evaluación de un anatomopatólogo central.
    5. Estadio 2 o 3 de fibrosis en la EHNA de acuerdo con el sistema de estadificación de la fibrosis de la CRN de la EHNA, según la evaluación de un anatomopatólogo central.
    E.4Principal exclusion criteria
    1. Known or suspected abuse of alcohol (> 20 g/day for women or > 30 g/day for men), alcohol dependence* or narcotics. (* = assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).
    2. Diagnosis of type 1 diabetes according to medical records.
    3. HbA1c > 9% at screening.
    4. History or presence of pancreatitis (acute or chronic).
    5. Calcitonin ≥ 50 ng/L at screening.
    6. Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Family is defined as a first degree relative.
    7. Body Mass Index (BMI) ≤ 25.0 or ≥ 45.0 kg/m^2 at the screening visit.
    8. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice).
    1. Confirmación o sospecha de abuso de alcohol (> 20 g/día en las mujeres o > 30 g/día en los varones); dependencia del alcohol* o de narcóticos. (* = evaluado mediante la Prueba de identificación de trastornos relacionados con el consumo de alcohol (cuestionario AUDIT)).
    2. Diagnóstico de diabetes tipo 1 registrado en la historia clínica.
    3. HbA1c > 9% en la selección.
    4. Antecedentes o presencia de pancreatitis (aguda o crónica).
    5. Calcitonina ≥ 50 ng/l en la selección.
    6. Antecedentes personales o familiares de neoplasia endocrina múltiple tipo 2 o carcinoma medular de tiroides. La familia se refiere a parientes de primer grado.
    7. Índice de masa corporal (IMC) ≤ 25,0 y ≥ 45,0 kg/m2 en la visita de selección (visita 1).
    8. Mujeres embarazadas, en período de lactancia, que pretendan quedarse embarazadas o que estén en edad fértil y no utilicen un método anticonceptivo adecuado (según exija la normativa o práctica local).
    E.5 End points
    E.5.1Primary end point(s)
    NASH resolution without worsening of fibrosis (yes/no)
    Resolución de la EHNA sin empeoramiento de la fibrosis (sí/no)
    E.5.1.1Timepoint(s) of evaluation of this end point
    After 72 weeks
    Al cabo de 72 semanas
    E.5.2Secondary end point(s)
    1. At least one stage of liver fibrosis improvement with no worsening of NASH (yes/no) (worsening defined as an increase of at least one stage of either lobular inflammation or hepatocyte ballooning according to NASH clinical research network (CRN) criteria).
    2. Change in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) (0-8)
    3. Change in stage of fibrosis according to the Kleiner fibrosis classification (0-4)
    4. Change in activity component of steatosis-activity-fibrosis (SAF) score (0-4)
    5. Change in fasting plasma glucose (FPG)
    6. Change in glycosylated haemoglobin A1c (HbA1c)
    7. Change in serum enhanced liver fibrosis (ELF)
    1. Mejoría de la fibrosis hepática en al menos un estadio, sin empeoramiento de la EHNA (sí/no) (empeoramiento definido como un aumento de al menos un estadio de la inflamación lobular o balonamiento de los hepatocitos conforme a los criterios de la CRN de la EHNA).
    2. Variación del Índice de actividad de la EsHNA (NAS) (0-8)
    3. Variación del estadio de fibrosis conforme a la clasificación de fibrosis de Kleiner (0-4)
    4. Variación del componente de actividad del índice de esteatosis-actividad-fibrosis (SAF) (0-4)
    5. Variación de la glucosa plasmática en ayunas (GPA)
    6. Variación de la hemoglobina glucosilada tipo A1c (HbA1c)
    7. Variación de la fibrosis hepática (AFH) en suero
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. After 72 weeks
    2. – 7. From baseline to week 72
    1. Al cabo de 72 semanas
    2. - 7. Entre el momento basal y la semana 72
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial6
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA47
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    European Union
    Japan
    Russian Federation
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days11
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days11
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 316
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 56
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 210
    F.4.2.2In the whole clinical trial 372
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-02-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-01-16
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-03-19
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 00:26:54 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA